Original Article

MicroRNA-30a-3p functions as a tumor suppressor in renal cell carcinoma by targeting WNT2

Lingqi Liu, Liang Chen, Tianpeng Wu, Huijun Qian, Sixing Yang

Department of Urology, Renmin Hospital of Wuhan University, Wuhan 430060, Hubei, China

Received February 20, 2019; Accepted July 13, 2019; Epub August 15, 2019; Published August 30, 2019

Abstract: The expression and function of microRNA (miR)-30a-3p in several types of human cancer have been explored. However, the biological function of miR-30a-3p in renal cell carcinoma (RCC) remains largely unknown. In this study, we demonstrate that expression of miR-30a-3p is down-regulated in RCC tissues compared to adjacent normal tissues. Furthermore, ectopic expression of miR-30a-3p significantly suppressed the proliferation, migration, and invasion of a human RCC cell line in vitro, while miR-30a-3p inhibited tumor growth in vivo as well. TargetScan software identified Wnt2 as a potential direct target of miR-30a-3p. To confirm this relationship, Wnt2 was ectopically expressed. The effects of miR-30a-3p on RCC cell proliferation and invasion were subsequently restored. Therefore, the results of this study support an anti-tumor role for miR-30a-3p in RCC progression which is potentially mediated via Wnt2.

Keywords: Renal cell carcinoma, MicroRNA-30a-3p, WNT2

Introduction

Renal cell carcinoma (RCC) is currently the most common urologic malignancy diagnosed. It accounts for 2.3% [1] of all adult malignancies and for approximately 5% [2] of epithelial cancers worldwide. Advances in RCC therapy over the past few decades have enhanced patient outcomes [3]. However, the 5-year survival rate for patients who are diagnosed at a metastatic stage of RCC remains less than 10% [4]. Therefore, the identification of factors involved in RCC tumorigenesis and progression is imperative in order to identify novel targets and improve the clinical outcome of patients with metastatic RCC.

MicroRNAs (miRNAs) are a class of highly conserved, noncoding RNAs which are approximately 22 nucleotides in length and endogenously expressed. MiRNAs have been shown to negatively regulate a large number of genes by binding to the 3’-untranslated region (UTR) of corresponding target mRNAs [5, 6]. It has also been demonstrated that a variety of miRNAs are dysregulated in various types of human cancer, including RCC [6-8]. MiRNAs have been found to function as either tumor suppressors or oncogenes, depending on the role of their target genes. We hypothesize that a better understanding of the role of miRNAs in RCC will provide a new approach for management of this disease.

MiR-30a is dysregulated in many types of cancer, including glioma and lung cancer [9]. In a recent study, it was revealed that miR-30a suppresses RCC progression by targeting disintegrin and metalloproteinase domain-containing protein 9 (ADAM9) [10]. Similarly, miR-30a-3p, a member of the miR-30 family, is down-regulated in both high grade and advanced stage RCC [12]. However, the gene(s) which miR-30a-3p targets to affect RCC progression and metastasis remain unknown, and identification of these target(s) requires further investigation.

Here, we investigated the role of miR-30a-3p in an RCC cell line to explore its potential for mediating tumor growth and metastasis and for serving as a therapeutic target in RCC. We demonstrate that miR-30a-3p suppressed the proliferation, migration, and invasion of a human RCC cell line. In addition, miR-30a-3p inhibited tumor growth in vivo. We identify Wnt2 as a direct target of miR-30a-3p, and restoration of
MiR-30a-3p acts as a tumor suppressor in RCC

Wnt2 is shown to reverse the anti-tumor effects of miR-30a-3p in a RCC cell line. Collectively, these findings indicate that miR-30a-3p is a promising target and should be further investigated in RCC.

Materials and methods

Human tissue sample collection

This study was approved by the ethical board of Renmin Hospital of Wuhan University and it complies with the Declaration of Helsinki. Thirty pairs of RCC tissues and adjacent normal renal tissues were collected from patients undergoing radical nephrectomy at Renmin Hospital of Wuhan University (Hubei, China). Informed consent was obtained for each sample collection.

Cell lines, cell culture, and cell transfection

Human RCC cell lines, A498, Caki-1 and 786-O, were purchased from American Type Culture Collection (ATCC, Rockville, MD, USA). In addition, a normal renal cell line (HK-2) was purchased from the Cell Bank of the Chinese Academy of Sciences (Shanghai, China). All four cell lines were cultured in Dulbecco’s modified Eagle’s medium (Invitrogen, Carlsbad, CA, USA) supplemented with 10% fetal bovine serum (FBS, Gibco Life Technologies, Grand Island, NY, USA), 1% glutamine, and 1% penicillin/streptomycin (Invitrogen). Cell cultures were maintained at 37°C in a humidified atmosphere containing 5% CO₂. A miR-30a-3p mimic and a negative control were purchased from GenePharma (Shanghai, China) and transfected into cells with Lipofectamine 2000 (Invitrogen), according to the manufacturer’s protocol.

Quantitative reverse-transcriptase PCR (qRT-PCR)

Total RNA from tissues and cells was harvested with TRIzol reagent (Invitrogen) and purified with a RNeasy Mini kit (Qiagen, Valencia, CA, USA), according to the manufacturer’s instructions. A SYBR-Green PCR master mix (Applied Biosystems, Foster City, CA, USA) and 7500 Real-time PCR system (Applied Biosciences) were used for qRT-PCR assays. All of the reactions were setup in triplicate. The PCR primers used included: miR-30a-3p: 5’-CGCTTTCAAGTCGAGATTTGCTTGTGG-3' and 5’-GTGACGGTGCTCCGAGGTGCTG-3'; U6: 5’-CTCGTTCCTCCGACGAGAT-3' and 5’-AACGCTTTCAATTTGCGT-3'; 18S: 5’-CATTCGTATTGGCGTCG-3' and 5’-TGACGAGATTTGGCTGTGATGTTTCT-3'. A relative quantification value for each gene was calculated according to the 2^{-ΔΔCT} method with U6 used as an internal control.

MTT, colony formation, and cell cycle assays

Cell proliferation was determined in 3-(4,5-dimethylthiazol-2-yl)-2,5-diphenyltetrazolium bromide (MTT) assays which were performed according to the manufacturer’s protocol (Sigma-Aldrich, St. Louis, MO, USA). Optical density (OD) was measured at 490 nm with an enzyme immunoassay instrument (BioRad, Hercules, CA, USA). For colony formation assays, cells were transfected with the indicated constructs and then seeded into 6-well plates in growth medium to grow medium to grow. After 7 d, the colonies present were fixed with 4% formaldehyde and then stained with 0.5% crystal violet. Stained colonies with a diameter greater than 1 mm were counted. To analyze cell cycle distribution, cells were harvested, washed, and fixed with 70% ethanol overnight at 4°C. The cells were subsequently resuspended in fluorescence-activated cell sorting (FACS) solution supplemented with RNase and propidium iodide (PI). Cell cycle distribution was analyzed with a FACScan flow cytometer (BD Biosciences).

Cell migration assay

Twenty-four well Transwell plates (8-μm pore size, BD Biosciences, Franklin Lakes, NJ, USA) were used to perform cell migration assays. Briefly, 48 h after 786-O cells were transfected with the indicated constructs, aliquots of 100,000 cells from each transfection were loaded into the collagen IV-coated upper chambers. The lower chambers were filled with 0.4 ml DMEM containing 10% FBS. After 24 h, the cells were fixed with 10% formalin and stained with 0.1% crystal violet solution. The cells that migrated were imaged and counted in five randomly selected fields under a light microscope at × 200 magnification. All of the assays were performed in triplicate.

Wound healing assay

Cell migration was also evaluated in wound healing assays. Briefly, cells were seeded into 6-well plates (25,000 cells/well). After 24 h, the
MiR-30a-3p acts as a tumor suppressor in RCC

Figure 1. MiR-30a-3p is down-regulated in RCC specimens and cell lines. A. Relative expression of miR-30a-3p was detected in 30 paired clinical RCC specimens and adjacent normal tissues by qRT-PCR. B. The expression level of miR-30a-3p in 3 RCC cell lines (786-O, A498, Caki-1) and one normal renal cell line (HK-2) was also analyzed by qRT-PCR. U6 served as an internal reference. All data are expressed as the mean ± SD of three independent experiments. *P < 0.05.

Figure 2. MiR-30a-3p suppresses RCC cell proliferation. A. Relative expression of miR-30a-3p was detected by qRT-PCR in 786-O cells after transfections with miR-30a-3p and a negative control (NC). B. MTT assays were performed to measure 786-O cell proliferation following transfection with miR-30a-3p or NC. C. The colonies formed after transfection with miR-30a-3p or NC are shown. D. Stained colonies with a diameter greater than 1 mm were counted. E. Cell cycle distribution was analyzed in 786-O cells transfected with miR-30a-3p or NC. All data are expressed as the mean ± SD for three independent experiments. *P < 0.05. NC, negative control.

Western blotting was performed as previously described [13]. Briefly, cells were lysed in a modified radioimmunoprecipitation (RIPA) buffer.
MiR-30a-3p acts as a tumor suppressor in RCC

Figure 3. MiR-30a-3p inhibits tumor growth in vivo. A. Tumor growth curves were generated based on measurements of tumor volume that were recorded weekly following the injection of tumor cells. B. Tumor weights were recorded five weeks after the initial injections of tumor cells. All data are expressed as the mean ± SD. *P < 0.05. NC, negative control.

Figure 4. MiR-30a-3p inhibits RCC cell migration. A. Representative images (200 × magnification) of 786-O cells stained with crystal violet after transfection with miR-30a-3p or NC. B. Quantification of the number of cells that migrated in Transwell assays. Cells were counted in five randomly selected fields. C. Wound healing assays were performed to assess cell migration. Overexpression of miR-30a-3p decreased the numbers of migrating 786-O cells after 24 h. D. Quantification of the cell migration data. The data presented are the mean ± SD. *P < 0.05. NC, negative control.

Statistical analysis

The results of multiple experiments are presented as the mean ± standard deviation (SD) from three separate experiments and analyzed using SPSS16.0 statistical software. Student’s t-test was used to evaluate the statistical significance of differences between groups. P-values less than 0.05 were considered statistically significant.

Results

Expression of miR-30a-3p was detected in 30 RCC specimens and matched adjacent normal tissues by qRT-PCR. The levels of miR-30a-3p were significantly lower in the clinical RCC specimens compared to the corresponding non-tumor tissues (Figure 1A). The expression levels of miR-30a-3p detected in three RCC cell lines (A498, Caki-1, and 786-O) were also markedly reduced compared with the normal human renal cell line, HK-2 (Figure 1B).

To examine the role of miR-30a-3p in RCC cell growth, 786-O cells were transfected with a miR-30a-3p mimic or negative control. After 72
MiR-30a-3p acts as a tumor suppressor in RCC

MiR-30a-3p inhibits tumor growth in vivo

To study the effect of miR-30a-3p on RCC cell motility, wound healing and Transwell migration assays were performed. Following the transfection of miR-30a-3p, both the migration and invasion phenotypes of 786-0 cells were significantly suppressed (Figure 4A and 4B).

Wnt2 is the downstream target of miR-30a-3p in RCC cells

To identify genes targeted by miR-30a-3p, TargetScan software was used. Among the possibilities, Wnt2 was identified as a potential target (Figure 5A). To confirm this target, luciferase activity assays were performed. Transfection of miR-30a-3p resulted in a significant reduction in luciferase activity in the presence of the WT 3'-UTR of Wnt2 (Figure 5B). In contrast, no reduction in luciferase activity was observed in the presence of a mutated Wnt2 3'-UTR (Mut) in 786-0 cells (Figure 5B). Furthermore, overexpression of Wnt2 significantly suppressed both mRNA and protein levels of WNT2 (Figure 5C and 5D). In addition, miR-30a-3p markedly inhibited the expression of β-catenin (Figure 5D).

Restoration of Wnt2 reverses the anti-tumor effects of miR-30a-3p in 786-0 cells

To further verify a functional relationship between miR-30a-3p and Wnt2, we co-transfected 786-0 cells with a miR-30a-3p mimic and a vector to provide overexpression of Wnt2 (Figure 6A). Cell proliferation, colony formation, cell cycle, and migration assays were subsequently performed. Overexpression of Wnt2 significantly attenuated the inhibitory effect of miR-30a-3p on 786-0 cell growth (Figure 6B and 6C). Cell cycle arrest induced by miR-30a-3p was also reversed with overexpression of Wnt2 (Figure 6D). Furthermore, restoration of Wnt2 significantly promoted the inva-
MiR-30a-3p acts as a tumor suppressor in RCC

Discussion

It has been reported that miR-30a is a critical regulator in carcinogenesis and tumor progression by functioning as an oncogene or tumor suppressor gene [14, 15]. MiR-30a-3p is a member of the miR-30a family and a number of studies have indicated that miR-30a-3p plays an essential role in tumorigenesis [11, 16, 17]. MiR-30a-3p is down-regulated in hepatocellular carcinoma and can suppress tumor proliferation, metastasis, and invasiveness [11]. MiR-30a-3p has also been shown to be down-regulated in RCC [12]. To the best of our knowledge, the experiments described here provide the first evidence that miRNA-30a-3p can inhibit RCC progression by regulating Wnt2 expression. In both RCC cell lines and tissues, the expression level of miRNA-30a-3p was significantly down-regulated. Conversely, both in vitro and in vivo studies demonstrated that overexpression of miR-30a-3p inhibits RCC proliferation and growth. The migration potential of miR-30a-3p RCC cells was also decreased compared to control cells. Following the identification of Wnt2 as a direct target of miRNA-30a-3p, restoration of Wnt2 was shown to reverse miRNA-30a-3p-induced inhibition of cell proliferation. Thus, it appears that miRNA-30a-3p has a tumor suppressor role to negatively affect RCC progression.

The Wnt signaling pathway is frequently dysregulated in various types of tumors. Correspondingly, Wnt signaling has been found to have important roles in tumor development and progression, including specific roles in regulating cell proliferation, invasion, and migration [18-20]. In several cancers, the Wnt2/β-catenin pathway plays a crucial role in disease pathogenesis [17, 21, 22]. For example, Wnt2 has been shown to promote cancer progression by activating the Wnt/β-catenin pathway in both non-small cell lung cancer [23] and in colorectal cancer [24]. Moreover, Wnt2 induces pancreatic cancer metastasis through activation of the Wnt/β-catenin pathway [25, 26]. The present results demonstrate that Wnt2 is a direct target of miR-30a-3p in RCC cells. Moreover, miR-30a-3p overexpression correlates with Wnt2 down-regulation and subse-

Figure 6. Ectopic overexpression of Wnt2 reverses the anti-tumor effects induced by miR-30a-3p in 786-O cells. A. Western blot analysis of Wnt2 in 786-O cells transfected with the indicated constructs. Actin was detected as a loading control. B. MTT proliferation assay results for 786-O cells transfected with the indicated constructs. C. Number of 786-O colonies formed after transfections with the indicated constructs. D. Cell cycle distribution of 786-O cells after transfections with the indicated constructs. E. Wound healing assay results for 786-O cells after transfections with the indicated constructs. F. Cell migration data from Transwell chamber assays after transfection of 786-O cells with the indicated constructs. All data are presented as the mean ± SD. *P < 0.05. NC, negative control.
quent inhibition of cell proliferation and migration. These findings were confirmed when restoration of Wnt2 reversed the miR-30a-3p-induced inhibition of cell proliferation. Taken together, these data suggest that the tumor suppressor role of miR-30a-3p in RCC may be mediated via regulation of Wnt2 expression.

**Conclusion**

In summary, the results of this study indicate that miR-30a-3p is down-regulated in RCC specimens and cell lines and it plays an important role in the malignant progression of RCC cells by directly regulating Wnt2 expression. These findings suggest that miR-30a-3p may represent a potential therapeutic target for treatment of RCC and further studies are warranted.

**Acknowledgements**

This work was supported by Fundamental Research Funds for Central Universities (No. 2042014kf0624).

**Disclosure of conflict of interest**

None.

**Address correspondence to:** Dr. Lingqi Liu, Department of Urology, Renmin Hospital of Wuhan University, 99 Zhangzhidong Road, Wuhan 430060, Hubei, China. E-mail: llqfly@163.com

**References**


MiR-30a-3p acts as a tumor suppressor in RCC


